A detailed history of Two Sigma Investments, LP transactions in Atai Life Sciences N.V. stock. As of the latest transaction made, Two Sigma Investments, LP holds 407,183 shares of ATAI stock, worth $704,426. This represents 0.0% of its overall portfolio holdings.

Number of Shares
407,183
Previous 717,131 43.22%
Holding current value
$704,426
Previous $953,000 50.47%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.16 - $1.64 $359,539 - $508,314
-309,948 Reduced 43.22%
407,183 $472,000
Q2 2024

Aug 14, 2024

BUY
$1.27 - $2.6 $401,505 - $821,979
316,146 Added 78.84%
717,131 $953,000
Q1 2024

May 15, 2024

SELL
$1.5 - $2.19 $22,137 - $32,320
-14,758 Reduced 3.55%
400,985 $789,000
Q4 2023

Feb 14, 2024

BUY
$1.04 - $1.55 $135,526 - $201,986
130,314 Added 45.66%
415,743 $586,000
Q3 2023

Nov 14, 2023

SELL
$1.27 - $2.28 $122,444 - $219,821
-96,413 Reduced 25.25%
285,429 $368,000
Q2 2023

Aug 14, 2023

SELL
$1.44 - $2.19 $678,055 - $1.03 Million
-470,872 Reduced 55.22%
381,842 $656,000
Q1 2023

May 15, 2023

SELL
$1.17 - $2.7 $142,597 - $329,070
-121,878 Reduced 12.51%
852,714 $1.54 Million
Q4 2022

Feb 14, 2023

BUY
$2.38 - $3.55 $528,267 - $787,961
221,961 Added 29.49%
974,592 $2.59 Million
Q3 2022

Nov 14, 2022

BUY
$3.14 - $4.87 $64,329 - $99,771
20,487 Added 2.8%
752,631 $2.49 Million
Q2 2022

Aug 15, 2022

BUY
$3.03 - $5.32 $672,266 - $1.18 Million
221,870 Added 43.48%
732,144 $2.67 Million
Q1 2022

May 16, 2022

BUY
$4.66 - $7.66 $447,360 - $735,360
96,000 Added 23.17%
510,274 $2.6 Million
Q4 2021

Feb 14, 2022

BUY
$6.82 - $17.8 $2.83 Million - $7.37 Million
414,274 New
414,274 $3.16 Million

Others Institutions Holding ATAI

About ATAI Life Sciences N.V.


  • Ticker ATAI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 165,875,008
  • Market Cap $287M
  • Description
  • Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment o...
More about ATAI
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.